CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma

Top Cited Papers
Open Access
Abstract
Key Points Response to the CD38-targeting antibody daratumumab is significantly associated with CD38 expression levels on the tumor cells. Resistance to daratumumab is accompanied by increased expression of complement-inhibitory proteins.